Respimat Pharmaceuticals Antitrust Litigation
The drugs involved, Combivent Respimat and Spiriva Respimat, are inhalers used to treat asthma and COPD. The causation theory centers on Boehringer's alleged wrongful listing of device-only patents in the FDA Orange Book, which falsely claimed patent protection over the drug's active ingredients. This wrongful listing prevented generic competitors from entering the market, causing economic injuries such as overpayment and higher prices for consumers and payers. The injury was sustained over the period during which these wrongful listings remained in effect, starting around May 19, 2025.
2
Pending actions
2
Total actions filed
Active
Status
08/07/2025
Established
Who qualifies
Plaintiffs must have purchased or paid for Combivent Respimat or Spiriva Respimat during the class period, suffering economic harm such as overpayment or loss of access to lower-cost generics, caused by Boehringer's wrongful patent listings in the FDA Orange Book. The class period is at least from May 19, 2025, following the initial filings, and likely extends through ongoing litigation.
Products involved
- Combivent Respimat
- Spiriva Respimat
Alleged injuries
- Overpayment due to delayed generic entry
- Higher drug prices caused by anti-competitive patent listings
Settlement landscape
No publicly reported settlement estimates or case values are available as of the latest updates. The case remains active with ongoing proceedings and no final verdicts or settlement announcements.
Lead counsel
- DiCello Levitt
This page is generated from the official JPML pending-MDL report and public court records, refreshed monthly. It is provided for attorney reference and is not legal advice.
